Wa’el Hashad, CEO of Longeveron LGVN, was a guest recently on Benzinga’s All-Access.
Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product is Lomecel-B™, which is derived from the bone marrow of young healthy adult donors.
The company believes that by using the same cells that promote tissue repair, organ maintenance and immune system function, it can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging.
The company has just announced top-line results from its phase 2a trial for the treatment of Alzheimer's.
Learn more here:
Featured photo by Christopher Cassidy on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
